Company
Natera
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
7
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
NTRA
Nasdaq · Natera, Inc.
Public float
$21.8B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$2.31B
Fiscal year ending Dec 31, 2025
Net income
-$208M
Fiscal year ending Dec 31, 2025
R&D spending
$624M
Fiscal year ending Dec 31, 2025
Cash
$1.10B
As of Sep 30, 2026
Long-term debt
Not reported
Shares outstanding
145.0M
As of Oct 31, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2023 | $235M | – | – | – |
| 2022 | $433M | – | – | – |
| 2021 | $551M | – | – | $278M |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
- Signatera CDxBreakthroughPMA
P260004 · Decided May 15, 2026 · 106 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT07214532 · 725 participants (planned) · Start May 8, 2026 · Primary completion May 15, 2032
Device: ctDNA-Guided Treatment Strategy · For: Breast Neoplasms; Carcinoma, Ductal, Breast; Receptors, Estrogen (for ER-positive Requirement)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 50 sites in all
- A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.Pivotal-lookingNot yet recruiting
NCT07689812 · 920 participants (planned) · Start Jan 2027 · Primary completion Aug 2034
Device: Signatera Genome ultra-sensitive ctDNA blood test · For: NSCLC (Advanced Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Cancer); NSCLC (Non-small Cell Lung Carcinoma) and 12 more
- Signatera Assessment in Early-Stage Endometrial CancerPivotal-lookingNot yet recruiting
NCT07339384 · 1,010 participants (planned) · Start Oct 2026 · Primary completion Oct 2034
Device: Signatera Genome ultra-sensitive ctDNA blood test · For: Endometrial Cancer
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 12 sites in all
4 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.